Last reviewed · How we verify
ChAdOx1 nCoV-19
ChAdOx1 nCoV-19 is a viral vector vaccine that delivers the SARS-CoV-2 spike protein gene into cells to trigger an immune response against COVID-19.
ChAdOx1 nCoV-19 is a viral vector vaccine that delivers the SARS-CoV-2 spike protein gene into cells to trigger an immune response against COVID-19. Used for COVID-19 prevention in adults.
At a glance
| Generic name | ChAdOx1 nCoV-19 |
|---|---|
| Also known as | COVISHIELD |
| Sponsor | EuBiologics Co.,Ltd |
| Drug class | Viral vector vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine uses a replication-deficient chimpanzee adenovirus (ChAdOx1) as a vector to carry genetic instructions for producing the SARS-CoV-2 spike protein. Once administered, the vector enters host cells and expresses the spike protein, which stimulates both cellular and humoral immune responses. This primes the immune system to recognize and neutralize the actual SARS-CoV-2 virus upon exposure.
Approved indications
- COVID-19 prevention in adults
Common side effects
- Injection site pain
- Fatigue
- Headache
- Myalgia
- Fever
- Chills
Key clinical trials
- Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly
- The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01) (PHASE2, PHASE3)
- Phase II/III Study of the AVX/COVID-12 Vaccine Against COVID-19 Applied as a Booster. (PHASE2, PHASE3)
- Investigating a Vaccine Against COVID-19 (PHASE2, PHASE3)
- A Study of a Candidate COVID-19 Vaccine (COV001) (PHASE1, PHASE2)
- Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients
- Does Repeat Influenza Vaccination Constrain Influenza Immune Responses and Protection
- Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ChAdOx1 nCoV-19 CI brief — competitive landscape report
- ChAdOx1 nCoV-19 updates RSS · CI watch RSS
- EuBiologics Co.,Ltd portfolio CI